ghk-cu/tb-500/bpc-157/kpv bpc157 ghk cu kpv tb500 BLEND PEPTIDE (50MG/10MG Unlocking the Power of Peptides:
Description
A phase I safety study in healthy adults confirmed that subcutaneous MOTS-c injections at doses up to 10 mg produced no serious adverse events, with a pharmacokinetic profile supporting once-daily or every-other-day dosing [3]
Field of use: Vitamin B12deficiency that cannot be corrected with nutrition
at a dose of 500 g twice a week, 56 a dose lower than in most other trials
24 April 2010
